The therapeutic community is buzzing with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 target that’s showing significant efficacy in clinical trials for managing obesity. Unlike some existing weight loss approaches, retatrutide appears to offer a greater substantial loss in bo